Sugi Predict

Sugi Predict / Targets / EFHD2

EFHD2

EF-hand domain-containing protein D2 · Q96C19 · EFHD2 on Sugi Atlas →

0 patent compounds predicted against EFHD2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EFHD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) PHASE4COMPLETED
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia PHASE4COMPLETED
Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia PHASE1/PHASE2UNKNOWN
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) PHASE1UNKNOWN
Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy EARLY_PHASE1UNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer nanUNKNOWN
Cardiopulmonary and Right Ventricular Function in Health and Disease nanUNKNOWN
Human Epilepsy Genetics--Neuronal Migration Disorders Study nanRECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES) nanUNKNOWN
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers nanCOMPLETED
Family Blood Pressure Program - GENOA nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients nanCOMPLETED
Gene Analysis of Parkinson's Disease nanCOMPLETED
The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia nanCOMPLETED
Mechanisms Defending Fat Mass in Humans After Lipectomy nanCOMPLETED
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EFHD2 binder may also engage these)

ProteinNameSimilarity
Q9D8Y0 — 1.000 Q9D8Y0 →
A5D7A0 — 1.000 A5D7A0 →
Q4FZY0 — 0.999 Q4FZY0 →
Q9BUP0 — 0.997 Q9BUP0 →
Q17QM6 — 0.990 Q17QM6 →
Q9D4J1 — 0.990 Q9D4J1 →
O60784 — 0.973 O60784 →
Q8BML1 — 0.973 Q8BML1 →
Q5PQM2 — 0.972 Q5PQM2 →
Q9EQX4 — 0.972 Q9EQX4 →
F1QWK4 — 0.971 F1QWK4 →
Q9NSK0 — 0.971 Q9NSK0 →
O12940 — 0.971 O12940 →
Q9BQI0 — 0.971 Q9BQI0 →
Q86XE3 — 0.971 Q86XE3 →
O94851 — 0.971 O94851 →
Q5RDI4 — 0.970 Q5RDI4 →
Q8MKD5 — 0.970 Q8MKD5 →
Q9D7J7 — 0.970 Q9D7J7 →
O88746 — 0.970 O88746 →
O43815 — 0.970 O43815 →
P70483 — 0.970 P70483 →
TNNI3 Troponin I, cardiac muscle (Cardiac troponin 0.969 landscape →
Q4V872 — 0.968 Q4V872 →
A0A8I6A2H6 — 0.968 A0A8I6A2H6 →
Q9CTY5 — 0.968 Q9CTY5 →
Q58A65 — 0.968 Q58A65 →
F1RA39 — 0.968 F1RA39 →
Q3UJB0 — 0.968 Q3UJB0 →
Q9H0B6 — 0.968 Q9H0B6 →